Request demo
Picture of Rob Scoffin

Rob Scoffin

Rob is an expert in the fields of molecular modeling and cheminformatics. His DPhil is in Chemistry from the University of Oxford. Rob is passionate about applying computational methods to help meet medical challenges. He believes drug discovery and design can be streamlined and improved through the use of computational methods, resulting in better drugs being brought to market sooner. Rob is a Fellow of the Royal Society of Chemistry. Rob joined Cresset as CEO in 2010 and now also serves as Chairman of Cresset. During the time he has been leading the team, Cresset has further developed its software and contract research divisions from a very solid customer base, into a high-growth and profitable business. Rob also serves as co-Chairman for Torx Software, a collaboration between Cresset and Elixir Software. His previous roles include CEO of Amedis and VP, Europe at CambridgeSoft.

Science Resources

How the AI revolution can accelerate early drug discovery
Abstract In this article in Drug Target Review, Rob Scoffin and Matthew Habgood look to the future of drug discovery and the roles that artificial...

News Articles

Rapid and accessible in silico macrocycle design
Abstract Macrocyclization of pharmaceutical compounds plays an increasing role in drug discovery. Macrocycles can provide several advantages...
CEO’s end of year message 2018
Dr Robert Scoffin, CEO As we near the end of the year I’ve been reflecting on the progress we’ve made. During 2018 we’ve seen major developments in...
The virtuous circle: Cultivating closer ties between academia and industry
Academia and industry always have a lot to gain from cultivating close ties with each other. As with any relationship, getting the balance right...
Presentations from the Cresset User Group Meeting 2019
Thank you to all attendees who contributed to the success of the Cresset User Group Meeting 2019. As I’m sure you can appreciate, many of our...
CEO’s end of year message 2019
2019 has been another successful year for Cresset with significant growth and developments in both software and services. I want to express my...
Dr Andy Vinter 1943 – 2019
It is with sadness that I share the news that Dr Andy Vinter passed away on Monday 16th December 2019 after a short illness....
Lead-like libraries from 3D-fragments
Cresset Discovery Services has provided in silico design expertise and robust cheminformatics capabilities to Liverpool ChiroChem (LCC) in...
CEO’s end of year message 2020
I think it’s fair to say that 2020 will not go down in most people’s memory as a ‘classic’, but it’s bound to be a year that we remember, even if the events...
CEO’s end of year message 2021
I want to take the opportunity to thank all of our customers, existing and new, for their support of Cresset over the last 12 months. I also want to...
CEO’s end of year message 2022
As we near the end of another year, it falls to me to reflect on the events of 2022… This has been a very busy year for all at Cresset, and has seen very...
Navigating unprecedented changes in the biotechnology and biochemistry sectors
At BIO 2023, I spoke to the Life Sciences Knowledge Hub about how Cresset are navigating the unprecedented changes in the biotechnology and biochemistry...
Skeletal editing and removing the gap between CADD/AIDD and synthesis
In the fields of peptide and protein synthesis, there is a very efficient translation between design and synthesis – this operates generally via...
How the AI revolution can accelerate early drug discovery
AI will not replace drug discovery scientists, but drug discovery scientists who use AI will replace those who don’t Comment during EFMC meeting...
Future-proofing drug discovery through flexible platforms
The ability of a drug discovery solution to change and adapt is essential to meet the evolving needs of patients, industry requirements, and changing...
CEO end of year message 2023
As we near the end of another year, I am reflecting on what has been a year of contrasts and challenges. The contrasts have come in the form of much positive...
Torx® CEO end of year message 2023
Torx® Software has seen another fantastic year of growth with more customers, features, integrations, and team members joining us on our exciting...
Future-proofing Cybersecurity in Drug Discovery
The pharmaceutical and biotech sectors suffer more data security breaches than any other industry,​ with​ 53% result​ing​ ...
Overcoming key challenges in drug discovery and development: ADMET prediction with AI techniques
Bringing a new drug to market is a complex journey filled with challenges and hurdles. One crucial aspect is understanding and optimising the active...

Blog

Rapid and accessible in silico macrocycle design
Abstract Macrocyclization of pharmaceutical compounds plays an increasing role in drug discovery. Macrocycles can provide several advantages...
CEO’s end of year message 2018
Dr Robert Scoffin, CEO As we near the end of the year I’ve been reflecting on the progress we’ve made. During 2018 we’ve seen major developments in...
The virtuous circle: Cultivating closer ties between academia and industry
Academia and industry always have a lot to gain from cultivating close ties with each other. As with any relationship, getting the balance right...
Presentations from the Cresset User Group Meeting 2019
Thank you to all attendees who contributed to the success of the Cresset User Group Meeting 2019. As I’m sure you can appreciate, many of our...
CEO’s end of year message 2019
2019 has been another successful year for Cresset with significant growth and developments in both software and services. I want to express my...
Dr Andy Vinter 1943 – 2019
It is with sadness that I share the news that Dr Andy Vinter passed away on Monday 16th December 2019 after a short illness....
Lead-like libraries from 3D-fragments
Cresset Discovery Services has provided in silico design expertise and robust cheminformatics capabilities to Liverpool ChiroChem (LCC) in...
CEO’s end of year message 2020
I think it’s fair to say that 2020 will not go down in most people’s memory as a ‘classic’, but it’s bound to be a year that we remember, even if the events...
CEO’s end of year message 2021
I want to take the opportunity to thank all of our customers, existing and new, for their support of Cresset over the last 12 months. I also want to...
CEO’s end of year message 2022
As we near the end of another year, it falls to me to reflect on the events of 2022… This has been a very busy year for all at Cresset, and has seen very...
Navigating unprecedented changes in the biotechnology and biochemistry sectors
At BIO 2023, I spoke to the Life Sciences Knowledge Hub about how Cresset are navigating the unprecedented changes in the biotechnology and biochemistry...
Skeletal editing and removing the gap between CADD/AIDD and synthesis
In the fields of peptide and protein synthesis, there is a very efficient translation between design and synthesis – this operates generally via...
How the AI revolution can accelerate early drug discovery
AI will not replace drug discovery scientists, but drug discovery scientists who use AI will replace those who don’t Comment during EFMC meeting...
Future-proofing drug discovery through flexible platforms
The ability of a drug discovery solution to change and adapt is essential to meet the evolving needs of patients, industry requirements, and changing...
CEO end of year message 2023
As we near the end of another year, I am reflecting on what has been a year of contrasts and challenges. The contrasts have come in the form of much positive...
Torx® CEO end of year message 2023
Torx® Software has seen another fantastic year of growth with more customers, features, integrations, and team members joining us on our exciting...
Future-proofing Cybersecurity in Drug Discovery
The pharmaceutical and biotech sectors suffer more data security breaches than any other industry,​ with​ 53% result​ing​ ...
Overcoming key challenges in drug discovery and development: ADMET prediction with AI techniques
Bringing a new drug to market is a complex journey filled with challenges and hurdles. One crucial aspect is understanding and optimising the active...